News

Filter

Current filters:

CiplaPricing

Indian govt to penalize drugmakers for overcharging

Indian govt to penalize drugmakers for overcharging

06-05-2014

In a major crackdown, India's drug price regulator, the National Pharmaceutical Pricing Authority (NPPA)…

CiplaFinancialGlaxoSmithKlineIndiaPharmaceuticalPricing

India/USA trade dispute could impact AIDS treatment programs

10-03-2014

The trade dispute over intellectual property rights between the USA and India is set to derail the distribution…

Anti-viralsCiplaGenericsGilead SciencesGlaxoSmithKlineIndiaPatentsPricingUSA

India's Cipla cuts prices of three cancer drugs

12-11-2012

Following what Indian drugmaker Cipla (BSE: 500087) said was an "overwhelming response" on the price…

Asia-PacificcapecitabineCipladocetaxelerlotinibGenericsOncologyPatentsPfizerPharmaceuticalPricingSunitinib MalateSutent

Cipla slashes price of generic cancer drug Nexavar in India by 76%; other cuts too

04-05-2012

Indian drugmaker Cipla (BSE: 500087) has slashed the prices of certain life-saving cancer drugs used…

Asia-PacificAstraZenecaBayerCiplaGenericsIressaMerck & CoNexavarOncologyPharmaceuticalPricingTemodar

COMPANY SPOTLIGHT

Menarini

Back to top